{"id":226605,"date":"2025-04-15T05:58:13","date_gmt":"2025-04-15T05:58:13","guid":{"rendered":"https:\/\/evertise.net\/?p=116151"},"modified":"2025-04-15T05:58:13","modified_gmt":"2025-04-15T05:58:13","slug":"diagnostics-pcr-market-expected-to-reach-usd-10-87-billion-2032-is-to-grow-at-4-3-cagr-from-2025-2032","status":"publish","type":"post","link":"http:\/\/ipsnews.net\/business\/2025\/04\/15\/diagnostics-pcr-market-expected-to-reach-usd-10-87-billion-2032-is-to-grow-at-4-3-cagr-from-2025-2032\/","title":{"rendered":"Diagnostics PCR Market Expected To Reach USD 10.87 billion 2032, is to grow at 4.3% CAGR from 2025-2032"},"content":{"rendered":"

<\/span><\/p>\n


\nDiagnostics PCR Market size<\/span>\u00a0is expected to reach USD 10.87 billion by 2032. The industry is undergoing a transformation driven by increasing demand for durable, high-performance industrial components across various sectors.<\/span><\/p>\n

Market to Hit USD 10.87 Bn by 2032<\/strong><\/p>\n

Diagnostics PCR Market<\/a>\u00a0size<\/span>\u00a0was valued at USD 6.21 billion in 2024 and expected to expand at a compound annual growth rate (CAGR) of 4.3% from 2025-2032, reaching USD 10.87 billion by 2032. In 2024, Diagnostics PCR Market Size<\/span>\u00a0was valued at approximately USD 3.5 billion in North America and its Market share of 42%. Also, in Europe held a market share of 27.9% in the same year, equating to revenues of USD 2.8 billion in 2024.<\/span><\/p>\n

\"Diagnostics<\/p>\n

Leading market Players Fueling Industry Evolution<\/strong><\/p>\n

In 2024, the Thermo Fisher Scientific (United States) is valued approximately at USD 42.9 billion while Bio-Rad Laboratories (United States) is valued at USD 2.6 billion and Illumina (United States) is valued at USD 4.4 billion respectively in Diagnostics PCR Market.<\/span><\/p>\n

Reagents and Consumables is dominated by Product Type segment in terms of value, in 2024<\/strong><\/p>\n

This Reagents and Consumables sector dominates the Diagnostics PCR Market which the segment\u2019s market share is 55% in 2023. Reagents encompass essential components such as primers, probes, enzymes, and master mixes that enable DNA amplification and detection.<\/span><\/p>\n

To know the most attractive segments, click here for a free sample of the report:\u00a0https:\/\/www.stellarmr.com\/report\/req_sample\/Diagnostics-PCR-Market\/1361<\/a>\u00a0<\/strong><\/span><\/p>\n

Real-Time PCR is dominated by Product Technology segment in terms of value, in 2024<\/strong><\/p>\n

This Real-Time sector dominates the Diagnostics PCR Market which the segment\u2019s value is USD 6.35 billion holding market share 83% of market share in 2024. It offers rapid results and higher sensitivity. Real-time PCR holds the largest market share due to its accurate and quantitative nature, making it suitable for various diagnostic applications.\u00a0<\/span><\/p>\n

North America is estimated to be the largest dominating region in terms of value, during the forecast period<\/strong><\/p>\n

This is the largest region in Diagnostics PCR Market which the valued at approximately USD 3.5 billion in North America and its Market share of 42% in 2024. The region has seen considerable use of PCR-based diagnostic technologies, with a particular emphasis on real-time PCR.\u00a0<\/span><\/p>\n

Europe is estimated to be the Second-largest dominating region in terms of value, during the forecast period<\/strong><\/p>\n

This is the largest region in Diagnostics PCR Market which the valued at approximately USD 2.8 billion in Europe and its Market share of 27.9% in 2024. Europe is another prominent market for Diagnostics PCR, characterized by a robust healthcare sector and a proactive approach towards molecular diagnostics.\u00a0<\/span><\/p>\n

Diagnostics PCR Market Competitive Landscape<\/strong><\/p>\n

Thermo Fisher Scientific:<\/strong>\u00a0By 2024, this company earns revenue around USD 42.9 billion. Thermo Fisher was granted permission to produce these kits in India by the Central Drugs Standard Control Organization (CDSCO) in February 2023. Thermo Fisher has expanded its autoimmune diagnostics line through an exclusive distribution deal with Aesku Group.\u00a0<\/span><\/p>\n

Illumina:<\/strong>\u00a0Illumina\u2019s market value is USD 4.4 billion by 2024. Illumina maintained its dominance in NGS technology, providing platforms that enable comprehensive genomic analysis for diagnoses in oncology and genetic disorders. Illumina has won FDA approval for several of its diagnostic assays, cementing its position in the clinical diagnostics sector.<\/span><\/p>\n

Bio-Rad Laboratories (United States):<\/strong>\u00a0A leader in life science research and clinical diagnostics, played an important role in expanding PCR technologies and faced a number of market challenges. In 2024, the corporation generated $2.6 billion in revenue. In December 2024, the Royal Bank of Canada boosted its price target for Bio-Rad Laboratories from $369.00 to $481.00 while keeping a \u201coutperform\u201d rating, citing optimism about the company\u2019s strategic efforts and market position.<\/span><\/p>\n

To know the most attractive segments, click here for a free sample of the report:\u00a0https:\/\/www.stellarmr.com\/report\/enquire_now\/Diagnostics-PCR-Market\/1361<\/a>\u00a0<\/strong><\/span><\/p>\n

Emerging Trends in the Diagnostics PCR Market<\/strong><\/p>\n